*NEWS: CBio unveils lab-ready cell analysis system
A hardware startup developing analytical tools to solve industry challenges in cell analysis, unveiled its full featured system during an Investor Demo Day at UCI.
CBio is a tenant in UCI’s Calit2 Tech Portal and part of UCI’s Beall Applied Innovation incubator, known as the Wayfinder, will now start testing its device with engaged university labs and other biotech companies.
“We’ve come along way from the bulky lab instrument that started it all,” CEO David Charlot said in an Aug. 22 press release.
Charlot has a Ph.D. in bioengineering and is a seasoned entrepreneur with expertise commercializing cell measurement tools.
“Researchers seeking solutions to challenges holding back breakthroughs in drug development for antibiotic resistance and stem-cell therapy in Alzheimer’s or groups who need consistent and reliable measurement of their cells for quality control can now have access to a powerful technique proven to streamline identification of important cell differences,” he added.
CBio now heads to Tempe, AZ to start testing its proprietary microfluidics solution at the Hayes Lab at Arizona State University. Mark Hayes, the inventor of this technique, as well as a professor at the school of molecular sciences at ASU, will guide the test using CBio’s multichannel approach. The Hayes Lab has been working with this groundbreaking cell separation technique for over 14 years.
After the test at ASU, CBio heads north to test cellPhoresis with FredSense in Canada. FredSense, a Calgary-based company developing portable field kits to detect chemicals in water, uses bacteria as a biosensor and will test cellPhoresis as a quality control step within its cell engineering process.
CBio will publish the data from these tests in October. The data is expected to demonstrate the benefits of cellPhoresis.
The company plans to open a Series A round after it finises the pilot studies. It will be seeking $2 million.